SyntekaBio

SyntekaBio Equity Ratio

The Equity Ratio of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 68.29 %. In the previous year, Equity Ratio was 57.06 % — a change of 19.69% (higher).

Equity Ratio

68.29 %

YoY

19.69%

Last updated:

Equity Ratio of SyntekaBio is 2025 68.29 % . Equity Ratio of SyntekaBio was 2024 57.06 % . It decreases by 19.69% higher compared to the previous year.

The SyntekaBio Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
13.56 KRW
Jan 1, 2019
96.17 KRW
Jan 1, 2020
92.77 KRW
Jan 1, 2021
40.70 KRW
Jan 1, 2022
56.49 KRW
Jan 1, 2023
59.01 KRW
Jan 1, 2024
57.06 KRW
Jan 1, 2025
68.29 KRW
The SyntekaBio Equity Ratio history
YEAREquity RatioYoY
68.29 %+19.69%
57.06 %-3.31%
59.01 %+4.46%
56.49 %+38.80%
40.70 %-56.13%
92.77 %-3.54%
96.17 %+609.27%
13.56 %-112.16%
-111.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Equity Ratio of SyntekaBio is 68.29 % in 2025.

Equity Ratio of SyntekaBio changed from 57.06 % to 68.29 %, representing a 19.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SyntekaBio

All Key Metrics — SyntekaBio